Ifetroban Sodium

DRUG3 trials

Sponsors

Vanderbilt-Ingram Cancer Center, Jeffrey Rade, Cumberland Pharmaceuticals

Conditions

Cardiovascular DiseasesIdiopathic Pulmonary FibrosisMalignant Solid TumorVascular Dilation

Phase 2

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Active, not recruitingNCT03694249

Vanderbilt-Ingram Cancer CenterMalignant Solid Tumor

Start: 2018-12-12End: 2026-04-30Updated: 2024-06-27

Thromboxane Receptor Antagonist to Improve Endothelial Function

CompletedNCT03962855

Jeffrey RadeCardiovascular Diseases, Vascular Dilation

Start: 2019-09-20End: 2022-11-15Updated: 2024-12-05

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

RecruitingNCT05571059

Cumberland PharmaceuticalsIdiopathic Pulmonary Fibrosis

Start: 2024-01-31End: 2028-01-01Target: 128Updated: 2026-09-02